Propanc Biopharma, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Propanc Biopharma, Inc. on June 21, 2019. The Company, incorporated in Delaware with principal executive offices in Camberwell, Australia, reports the confirmation of regulatory approval for a corporate capital structure change.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The report focuses exclusively on the mechanics of a reverse stock split.
Material Changes
The primary material event is the approval of a 1-for-500 reverse stock split of the Company's common stock. Key details include:
- Effective Date: The split takes effect at the market open on June 24, 2019.
- Trading Symbol: The symbol will temporarily change to "PPCBD" for 20 business days before reverting to "PPCB".
- Share Conversion: Every 500 pre-split shares convert into 1 post-split share; fractional shares are rounded up.
- Authorized Shares: Fixed at 100,000,000 post-split.
- Adjustments: Outstanding options, warrants, and restricted stock units will be adjusted proportionally (share counts divided by 500, exercise prices multiplied by 500).
- CUSIP: The new CUSIP number is 74346N206.
Guidance, Outlook, and Risks
The filing contains no financial guidance, management outlook, or discussion of operational risks. The Company notes that stockholders holding shares in electronic form at brokerage firms do not need to take action, while those holding certificated shares will receive transmittal letters from the transfer agent, Action Stock Transfer Corporation.
Investor Verification Checklist
- Verify the temporary trading symbol "PPCBD" on the OTCQB market starting June 24, 2019.
- Confirm the adjustment of personal holdings, options, and warrants to reflect the 1-for-500 ratio.
- Check brokerage accounts for the automatic reflection of the split for electronic holders.
- Review the Certificate of Amendment (Exhibit 3.1) and Certificate of Correction (Exhibit 3.2) filed with the Delaware Secretary of State.